NEUROPATHIC PAIN MARKET ANALYSIS

Neuropathic Pain Market, by Drug Class (Tricyclic Anti-Depressant, Anticonvulsant, Local Anaesthesia, Opioids, Steroids, Others), By Indication (Diabetic neuropathy, Chemotherapy-induced Peripheral neuropathy and Others), By Distribution Channel (Retail Pharmacies, Drug Store and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2023
Code : CMI3656
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Neuropathic Pain Market: Key Developments

Major players in the market are focused on approval and launch of new products in order to expand their product portfolio. For instance, in March 2020, Senzer Pharmaceuticals a U.K. based pharmaceutical company secured the Investigational New Drug application and data package for its ongoing U.S. Food and Drug Administration registration program from its former U.S. strategic partner in order to get approval for its cannabinoid respiratory device for the treatment of side effects induced by anti-cancer treatments, specifically nausea, vomiting, and neuropathic pain.

Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in February 2020, NoNO Inc., a privately-held biotechnology company, reported that novel peptide, nerinetide, without any administration of alteplase, demonstrated medically important improvements in patients with acute ischemic stroke, in a multicenter, randomized, study.